Mazyar Shadman, MD,MPH
Mazyar Shadman, MD, MPH, is an associate professor at University of Washington (UW) and Fred Hutchinson Cancer Center (FHCC). He is a hematologic malignancies expert who specializes in treating patients with lymphoma/ chronic lymphocytic leukemia (CLL).
He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR-T cell), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL. He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies.
Dr. Shadman received his M.D. from Tehran University in Iran. He finished internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio. He returned to Seattle and completed his training in hematology and medical oncology fellowships at the UW and Fred Hutchinson Cancer Center. Dr. Shadman also earned an M.P.H. degree from UW and was a fellow for National Cancer Institute’s cancer research training program at Fred Hutch, where he studies cancer epidemiology.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Mustang BioTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PharmacyclicsTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GenentechTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AbbVieTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:TG TherapeuticsTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BeiGeneTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstraZenecaTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GenmabTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:MorphoSys/IncyteTopic:Ad BoardDate added:12/27/2022Date updated:11/03/2023Relationship end date:12/27/2022